The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNF alpha production was demonstrated in HEK293 cells transfected with TLR3(L412F)-encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways.
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males / Croci, S.; Venneri, M. A.; Mantovani, S.; Fallerini, C.; Benetti, E.; Picchiotti, N.; Campolo, F.; Imperatore, F.; Palmieri, M.; Daga, S.; Gabbi, C.; Montagnani, F.; Beligni, G.; Farias, T. D. J.; Carriero, M. L.; Di Sarno, L.; Alaverdian, D.; Aslaksen, S.; Cubellis, M. V.; Spiga, O.; Baldassarri, M.; Fava, F.; Norman, P. J.; Frullanti, E.; Isidori, A. M.; Amoroso, A.; Mari, F.; Furini, S.; Mondelli, M. U.; Chiariello, M.; Renieri, A.; Meloni, I.; Bruttini, M.; Tita, R.; Amitrano, S.; Pinto, A. M.; Mencarelli, M. A.; Rizzo, C. L.; Perticaroli, V.; Fabbiani, M.; Rossetti, B.; Zanelli, G.; Bargagli, E.; Bergantini, L.; D'Alessandro, M.; Cameli, P.; Bennett, D.; Anedda, F.; Marcantonio, S.; Scolletta, S.; Franchi, F.; Mazzei, M. A.; Guerrini, S.; Conticini, E.; Cantarini, L.; Frediani, B.; Tacconi, D.; Spertilli, C.; Feri, M.; Donati, A.; Scala, R.; Guidelli, L.; Spargi, G.; Corridi, M.; Nencioni, C.; Croci, L.; Caldarelli, G. P.; Spagnesi, M.; Piacentini, P.; Bandini, M.; Desanctis, E.; Cappelli, S.; Canaccini, A.; Verzuri, A.; Anemoli, V.; Ognibene, A.; Pancrazi, A.; Lorubbio, M.; Vaghi, M.; Monforte, A. D.; Merlini, E.; Miraglia, F. G.; Bruno, R.; Vecchia, M.; Ludovisi, S.; Girardis, M.; Venturelli, S.; Sita, M.; Cossarizza, A.; Antinori, A.; Vergori, A.; Emiliozzi, A.; Rusconi, S.; Siano, M.; Gabrieli, A.; Riva, A.; Francisci, D.; Schiaroli, E.; Paciosi, F.; Scotton, P. G.. - In: AUTOPHAGY. - ISSN 1554-8627. - 18:7(2022), pp. 1662-1672. [10.1080/15548627.2021.1995152]
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males
Venneri M. A.;Amitrano S.;Bandini M.;Cappelli S.;Girardis M.;Sita M.;Cossarizza A.;Riva A.;
2022
Abstract
The polymorphism L412F in TLR3 has been associated with several infectious diseases. However, the mechanism underlying this association is still unexplored. Here, we show that the L412F polymorphism in TLR3 is a marker of severity in COVID-19. This association increases in the sub-cohort of males. Impaired macroautophagy/autophagy and reduced TNF/TNF alpha production was demonstrated in HEK293 cells transfected with TLR3(L412F)-encoding plasmid and stimulated with specific agonist poly(I:C). A statistically significant reduced survival at 28 days was shown in L412F COVID-19 patients treated with the autophagy-inhibitor hydroxychloroquine (p = 0.038). An increased frequency of autoimmune disorders such as co-morbidity was found in L412F COVID-19 males with specific class II HLA haplotypes prone to autoantigen presentation. Our analyses indicate that L412F polymorphism makes males at risk of severe COVID-19 and provides a rationale for reinterpreting clinical trials considering autophagy pathways.
| File | Dimensione | Formato | |
|---|---|---|---|
|
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Licenza:
[IR] creative-commons
Dimensione
2.48 MB
Formato
Adobe PDF
|
2.48 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
